Full Press Release Details
raises 2006 guidance and issues financial guidance for
Ireland, December 15, 2006 - ICON (NASDAQ: ICLR), a global provider of
outsourced development services to the pharmaceutical, biotechnology and medical
device industries, today raised its existing 2006 guidance and announced
financial guidance for 2007.
result of our strong backlog and continuing new business awards we are raising
our net revenue forecast for 2006 to a range of $448 to $452 million. Net income
per diluted share is expected to be $1.28 to $1.30 including non cash stock
compensation expense in accordance with SFAS 123R.
revenue is expected to be in the range of $530 - $550 million, an increase
20% on the forecast 2006 revenue.
per diluted share including non cash stock compensation expense in accordance
with SFAS 123R is forecast to be in the range of $1.63 - $1.71. This represents
an increase of 29% on 2006.
company will hold a conference call today, December 15, 2006 at 09:00 EST [14:00
Ireland & UK]. A question and answer session will follow.
statements made in this Press Release may contain forward-looking statements
that involve a number of risks and uncertainties. In addition to the matters
described in this Press Release, the ability to maintain large client contracts
or enter into new contracts, maintain client relationships and the ability
manage the opening of new offices, the integration of new business mergers
acquisitions, as well as other risks and uncertainties detailed from time to
time in SEC reports filed by ICON, including its Form 20-F, F-1, S-8 and F-3,
may affect the actual results achieved by ICON. ICON disclaims any intent or
obligation to update these forward-looking statements.
financial information presented herein has been prepared in accordance with
is a global provider of outsourced development services to the pharmaceutical,
biotechnology and medical device industries. The Company specializes in the
strategic development, management and analysis of programs that support clinical
development - from compound selection to Phase I-IV clinical studies. ICON
have successfully conducted over 1,900 development projects and over 2,300
consultancy engagements across all major therapeutic areas. ICON currently
over 4,100 employees, operating from 48 locations in 30 countries. Further
information is available at www.iconclinical.com.
Investor Relations 1-888-381-7923 or
Murray CFO + 353 -1-291-2000